Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
356
resultados
Última actualización
04/10/2026 [07:34:00]
Resultados 200 a 225 de 356
Resumen de: CN122652060A
本发明公开了一种用于诊断阿尔茨海默病的标志物组合及其应用和试剂盒。本发明的标志物包含外周血中的STMN1蛋白、STMN1mRNA及hsa‑miR‑9‑5p，通过检测外周血样本中STMN1蛋白、STMN1mRNA和靶向STMN1基因的miRNAhsa‑miR‑9‑5p的含量，将数据输入预先经Logistic回归拟合训练得到的诊断模型，即可实现阿尔茨海默病的精准筛查与确诊。相较于脑脊液等侵入式检测方案，本发明采用外周血取样，操作简便、检测成本更低，适合临床大规模无创筛查。
Resumen de: WO2025137532A1
Disclosed herein are methods of measuring amyloid β protofibril levels in biological samples. Methods disclosed herein may detect amyloid β protofibril at femtomolar concentrations and selectively measure protofibril as compared to amyloid β monomers.
Resumen de: US20260251557A1
0000 A method includes contacting one or more volatile organic compounds (“VOCs”) evolved from a sample to one or more detection regions configured for sensitivity against one or more VOCs. The contacting causes a change to the detection regions that is visible to the human eye. The method also includes determining the presence or absence of a VOC by comparing the change to the detection regions to a key, with the key being a visible change. A system utilizing the method is also described.
Resumen de: US20260251664A1
0000 The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of dementia in a middle-aged individual within a specified timeframe, for example 5, 10, 15 and/or 20 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of dementia within 5, 10, 15 and/or 20 years. In another aspect, methods are provided for evaluating risk of dementia within 5, 10, 15 and/or 20 years in a middle-aged individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 6.
Resumen de: US20260251650A1
0000 The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
Resumen de: US20260251655A1
0000 The present invention is directed to methods for determining the level of PAM and/or its isoforms and/or fragments thereof in a bodily fluid or a tissue sample using an assay, wherein said assay is comprising at least one binder that is directed to a conformational epitope of PAM, and its use for diagnostic purpose.
Resumen de: WO2026178110A1
Disclosed is a method for the treatment of major depressive disorder (MDD), which includes administering to a human subject suffering from MDD, a therapeutically effective amount of an antibody selected from fezakinumab, ustekinumab, gusacitinib and dupilumab, and combinations thereof.
Resumen de: WO2026177204A1
The purpose of the present invention is to provide a novel naturally derived cellular vesicle staining agent that can easily fluorescently stain cellular vesicles and that is safe even when introduced into the body, and to provide a cellular vesicle staining agent having anti-inflammatory activity. The purpose of the present invention is also to provide a method for producing a cellular vesicle staining agent, whereby the cellular vesicle staining agent can be easily produced. Another purpose of the present invention is to provide a method for detecting cellular vesicles using the cellular vesicle staining agent. The present invention provides: a cellular vesicle staining agent comprising chlorophyll or a chlorophyll derivative; an anti-inflammatory agent comprising chlorophyll or a chlorophyll derivative as an active ingredient; a method for producing a cellular vesicle staining agent, the method comprising a step for extracting a cellular vesicle staining agent from a photosynthetic organism; and a method for detecting a cellular vesicle in a sample or in a body using the cellular vesicle staining agent.
Resumen de: WO2026175415A1
Disclosed is a preparation technical method capable of preparing a large number of pathogenic tau proteins having a pathological conformation similar to that in the brain of a patient with neurodegenerative diseases by means of in vitro preparation and continuous multi-round amplification. The method can achieve continuous multi-round amplification of a patient brain-derived pathological tau protein by using only a small amount of the patient brain-derived pathological protein as a template, a recombinant human-derived tau protein monomer, and a negatively charged polyanion compound as an inducing cofactor, thereby achieving the in vitro preparation of a large amount of the pathological tau protein. In addition, the pathological tau protein prepared by the method can maintain the special pathological conformation of the original tau protein of the disease, has the same pathological activity as the original tau protein, and can be used for probe screening, antibody preparation, and verification model development.
Resumen de: AU2025374616A1
Methods of detecting analytes in a sample are described herein using chemiluminescent labels and branched DNA. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes such as exosome protein biomarkers in samples.
Resumen de: WO2026176083A1
The present invention relates to a method for diagnosing a patient having a neurological (including neuromuscular) disorder, such as ALS. The invention further relates to a method for distinguishing between neurological disorders, said method extending to include the ability to discriminate one subtype from other subtypes of the same disorder.
Resumen de: US20260251568A1
Disclosed herein is a device for chiral sensing comprising a chiral plasmonic substrate, wherein when the device is assembled together with a first light source, a liquid sample comprising a plurality of chiral analytes, a second light source, and an instrument, the first light source is configured to illuminate the chiral plasmonic substrate with electromagnetic radiation; and the second light source is configured to illuminate the chiral plasmonic substrate with circularly polarized electromagnetic radiation. The instrument is configured to process electromagnetic signal from the first light source and the second light source to determine a property of the liquid sample.
Resumen de: US20260251634A1
A method of analyzing neurons includes: identifying a cell region by identifying a region of a neurite or a region of a cell body of a neuron on the basis of time-series images obtained by imaging the neuron in time series; detecting aggregates by imaging, in time series, first fluorescent protein tagged to specific protein expressed in the neuron and detecting presence or absence of aggregates of the specific protein aggregated in the region of the neurite or the region of the cell body identified in the identifying the cell region on the basis of luminance of the first fluorescent protein included in the time-series images; and performing an analysis by classifying the neuron into a plurality of groups on the basis of a detection result of the detecting the aggregates and analyzing a survival state of the neuron for each of the groups.
Resumen de: US20260248877A1
0000 The present invention provides inhibitory peptides for use in the diagnostic and/or treatment of tauopathies, in particular Alzheimer's Disease and Pick's Disease. The inhibitory peptides comprise a hexapeptide sequence that specifically inhibits interactions of the PHF6 sequence within pathological Tau protein.
Resumen de: US20260250647A1
0000 The present disclosure relates to a chimeric protein molecule comprising a degradation domain including an E3 ubiquitin ligase motif without lysine residues and a targeting domain comprising a substrate-binding motif which is heterologous to the E3 ubiquitin ligase motif. A linker couples the degradation domain to the targeting domain. Also disclosed are compositions as well as methods of treating a disease, substrate silencing, forming a ribonucleoprotein, screening agents for therapeutic efficacy against a disease, and methods of screening for disease biomarkers, as well as mRNA molecules, vectors, and encapsulated nucleic acid molecules encoding chimeric protein molecules.
Resumen de: WO2026176371A1
The present disclosure is related to drug delivery compositions containing extracellular vesicles having a therapeutic by utilizing visceral sensory neurons, a method using thereof for delivering the drugs to central nervous system and an organoid on chip model comprising a three-compartment axis-on-a chip for testing delivery of the drug containing EV over BBB, wherein the compositions comprising bacterial extracellular vesicles (EV) and therapeutics, wherein the drug or the therapeutic is encapsulated within the EV or attached or conjugated to EV.
Resumen de: WO2026178362A1
Described herein are polypeptide useful for identifying compound for modulating aberrant protein condensates. The polypeptide comprise a condensate-modulating protein, a first biomarker polypeptide, a barcoding biomarker polypeptide. When inside a cell, the non-natural polypeptide exist as multiple fragments, including a first fragment comprising the condensate-modulating protein and the first biomarker polypeptide, and a second fragment comprising the barcoding biomarker polypeptide. The barcoding biomarker polypeptide is uniquely associated with and identifies the cell expressing associated condensate-modulating protein. Also described is a polynucleotide encoding the non-natural polypeptide, a library of the polynucleotide, and a method of identifying compound for modulating aberrant protein condensates using the non-natural polypeptide, the construct, and/or the library.
Resumen de: WO2026178077A1
The present disclosure relates to methods and compositions for editing an AMPK polynucleotide encoding an AMPK protein. The disclosure also relates to methods and compositions for modulating activity of an AMPK protein, for promoting activation of an AMPK protein, for repairing function of a pathogenic AMPK protein, and methods for regulating energy homeostasis and/or for treating or preventing an AMPK-associated disease or condition in a subject.
Resumen de: US20260251541A1
0000 The present invention relates to a method of fixing extracellular vesicles. The method includes providing a sample containing extracellular vesicles and contacting the sample with a non-reversible cross-linking agent and, optionally, an aldehyde-containing fixative. Preferably the non-reversible cross-linking agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. The method also includes imaging the fixed extracellular vesicles for the determination or exclusion of disease or disorder in a clinical sample. The present invention also relates to a kit for fixing extracellular vesicles in a biological sample.
Resumen de: US20260251660A1
The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
Resumen de: US20260250375A1
0000 The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
Resumen de: US20260251665A1
0000 A method of aiding diagnosis of a disease or condition in a subject, wherein the method comprises comparing a level of at least one natriuretic peptide detected in a biological sample obtained from the subject with a reference level of the at least one natriuretic peptide, wherein the biological sample is an oral mucosal transudate (OMT) sample obtained from one or more mucous membranes inside the mouth of the subject.
Resumen de: EP4796930A2
Disclosed herein are methods of detecting a plurality of targets comprising different nucleic acid sequences or different proteins within an optically resolved volume of a cell in situ.
Resumen de: EP4796929A2
0001 A method is provided for determining the presence of soluble, misfolded α-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric α-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded α-synuclein aggregate is present in the biological sample.
Nº publicación: EP4796928A1 26/08/2026
Solicitante:
UNIV AUT\u00D2NOMA DE BARCELONA [ES]
Universitat Aut\u00F2noma de Barcelona
Resumen de: EP4796928A1
The present disclosure relates to an in vitro method for diagnosing Alzheimer's disease (AD) in a subject, the method comprising a step of determining the level of β-secretase 1 protein (BACE-1) comprised in a population of brain-derived extracellular vesicles (BDEVs) in an isolated sample obtained from the subject, particularly wherein the population of BDEVs carry neuroligin-3 (NLGN3), wherein when the level of BACE-1 is equal to or higher than a reference this is indicative of a positive diagnosis of Alzheimer's disease. Also provided herein are methods of determining the classification of a subject according to the A/T/N system, methods for recommending a medical regimen, methods for determining therapeutic efficacy of a medical regiment, as well as methods of treatment for AD and AD-associated pathologies in a subject. Finally, the present disclosure provides kits and devices comprising: a) means for capturing a population of brain-derived extracellular vesicles; b) means for detecting the presence and/or for determining the level of BACE-1 protein; and optionally, c) a solid support.
BOPI
Sede Electrónica
